BEUDAMED
    FDA Adverse Event Injury Summary report: N

    RENÚ GEL, 1.5CC

    MDR report key: 8229240 · Received January 8, 2019

    Report

    Report Number
    3007225376-2019-00001
    Event Type
    Injury
    Date Received
    January 8, 2019
    Date of Event
    October 10, 2018
    Report Date
    February 11, 2019
    Manufacturer
    CYTOPHIL, INC.
    Product Code
    MIX
    UDI-DI
    00856509002935
    PMA / PMN Number
    K150400
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    NJ, US
    Reporter Occupation
    PHYSICIAN

    Narratives

    Additional Manufacturer Narrative · 0

    INJECTION RELATED EVENTS ARE A KNOWN COMPLICATION IN VOCAL FOLD AUGMENTATION PROCEDURES. "INJECTABLE RELATED ISSUES, PARTICULARLY SUPERFICIAL INJECTION, REMAIN PROBLEMATIC IN A SMALL PROPORTION OF PATIENTS." (SULICA L, ROSEN CA; POSTMA GN, SIMPSON B, AMIN M, COUREY M, MERATI A, CURRENT PRACTICE IN INJECTION AUGMENTATION OF THE VOCAL FOLDS: INDICATIONS, TREATMENT PRINCIPLES, TECHNIQUES, AND COMPLICATIONS, LARYNGOSCOPE 2010;120:319-325). IT IS ALSO WELL KNOWN THAT FOR VOCAL FOLD AUGMENTATION DEVICES WITH A SHORT LIFETIME, THESE ISSUES ARE EXPECTED TO RESOLVE WITH TIME. PROPER NEEDLE PLACEMENT (PRIOR TO INITIATING THE INJECTION) IS OF CRITICAL IMPORTANCE DURING A VOCAL FOLD AUGMENTATION PROCEDURE. A REVIEW OF THE RENÚ GEL INSTRUCTIONS FOR USE (IFU) CONFIRMED THAT THERE ARE PROPER INSTRUCTIONS AND A PERTINENT WARNING REGARDING PROPER NEEDLE PLACEMENT: WARNING: CONFIRM PLACEMENT OF THE NEEDLE TIP VISUALLY BEFORE INITIATING RENU GEL INJECTION. INSTRUCTIONS: "PLACE THE NASOPHARYNGOSCOPE TO PRECISELY VISUALIZE THE NEEDLE POSITION AND RENÚ® GEL VOCAL FOLD IMPLANT VOLUME DURING AUGMENTATION. WITH NEEDLE LOCATION VISUALLY CONFIRMED THROUGH NASOPHARYNGOSCOPE, SLOWLY PUSH THE PLUNGER SHAFT OF THE SYRINGE TO START THE INJECTION." CYTOPHIL, INC. CONDUCTED A REVIEW OF THE RENÚ GEL DEVICE MANUFACTURING AND STERILIZATION RECORDS ASSOCIATED WITH THIS COMPLAINT AND CONFIRMED THAT THE DEVICE WAS MANUFACTURED IN ACCORDANCE WITH SPECIFICATIONS. ADDITIONALLY, TO DATE, CYTOPHIL, INC. HAS NOT RECEIVED ANY OTHER REPORTS OF VOCAL FOLD STIFFNESS, SPECIFICALLY RELATED TO THIS LOT, NOR FOR ANY OTHER CYTOPHIL DEVICES. THE TREATING PHYSICIAN REPORTED THAT THE PATIENT DECLINED TO HAVE THE IMPLANT EXCISED WHEN THE ISSUE PRESENTED. THE PHYSICIAN ALSO REPORTED THAT THE PATIENT DOES NOT WISH TO PURSUE ANY FURTHER TREATMENT, AND HAS DEFERRED FURTHER FOLLOW UP RELATED TO THE STATUS OF HIS VOCAL FOLD STIFFNESS TO AN UNSPECIFIED DATE. THUS AT THIS POINT, IT IS UNKNOWN WHETHER THE PATIENT'S VOCAL FOLD STIFFNESS WILL RESOLVE ITSELF WITH TIME. THE PHYSICIAN REPORTED THAT DURING THE PROCEDURE, THE PATIENT WAS "MOVING AROUND AND COUGHING" AND THAT THIS BEHAVIOR COULD THEORETICALLY LEAD TO MISPLACEMENT OF THE INJECTABLE INTO A SUPERFICIAL LAYER OF THE VOCAL FOLD. CYTOPHIL, INC HAS CONCLUDED ITS COMPLAINT INVESTIGATION AND IS UNABLE TO DEFINITIVELY DETERMINE THE ROOT CAUSE OF THE REPORTED VOCAL FOLD STIFFNESS. ALTHOUGH NO DEFINITIVE RELATIONSHIP CAN BE CONCLUDED, THE PATIENT'S MOVEMENT DURING NEEDLE PLACEMENT MAY HAVE PLAYED SOME ROLE IN THE PATIENT SUBSEQUENTLY DEVELOPING VOCAL FOLD STIFFNESS. THE COMPLAINT IS BEING CLOSED AND WILL BE TRACKED AND TRENDED.

    Additional Manufacturer Narrative · 1

    CYTOPHIL, INC. REVIEWED THE MANUFACTURING, STERILIZATION, AND POST-STERILIZATION RECORDS FOR RENÚ GEL LOT Y708-00047. THIS REVIEW CONFIRMED THAT ALL DEVICES WERE MANUFACTURED IN ACCORDANCE WITH SPECIFICATIONS. THE PHYSICIAN REPORTED THAT THE RENÚ GEL, 1.5CC DEVICE ASSOCIATED WITH THE (B)(6) 2018 INJECTION HAD BEEN DISCARDED AND WAS NOT AVAILABLE FOR EVALUATION. CYTOPHIL, INC. HAS REVIEWED ITS COMPLAINT FILES FOR ANY SIMILAR TYPE COMPLAINTS, BOTH FOR THE REPORTED LOT, AND FOR ALL PRODUCTION LOTS DATING BACK TO 2015. THERE HAVE BEEN NO OTHER COMPLAINT REPORTS RECEIVED BY CYTOPHIL OF VOCAL FOLD STIFFNESS POST-INJECTION, WITH RENÚ INJECTABLE PRODUCTS. THE COMPLAINT INVESTIGATION IS ON-GOING. A SUPPLEMENTAL REPORT WILL BE PROVIDED.

    Description of Event or Problem · 1

    THE PATIENT WAS REPORTED TO HAVE BEEN DIAGNOSED WITH RIGHT VOCAL FOLD PARESIS VIA A VIDEOSTROBOSCOPY PERFORMED ON (B)(6) 2018. THE ETIOLOGY OF THE PARESIS IS UNKNOWN. ON (B)(6) 2018, THE PATIENT UNDERWENT PERCUTANEOUS INJECTION WITH 0.6 CC OF RENÚ GEL THROUGH THE CRICOTHYROID. THE PHYSICIAN REPORTED THAT THE PATIENT WAS MOVING AND COUGHING DURING THE PROCEDURE. THE PHYSICIAN CONFIRMED THAT THE PATIENT WAS ABLE TO PHONATE ON (B)(6) 2018 VIA AN EXAM FOLLOWING THE INJECTION. THE PATIENT'S VOICE WAS DESCRIBED AS "HOARSE DYSPHONIA" AND THE PATIENT'S EXAM WAS NOTED TO BE "WITHIN NORMAL LIMITS." THE PATIENT WAS SEEN FOR FOLLOW-UP ON (B)(6) 2018. THE PHYSICIAN REPORTED THAT THE PATIENT PRESENTED WITH "DECREASED AMPLITUDE OF THE MUCOSAL WAVE AND ECCHYMOSIS ON THE RIGHT VOCAL FOLD." THE ECCHYMOSIS WAS REPORTED TO HAVE RESOLVED AND UNILATERAL (RIGHT SIDE ONLY) VOCAL FOLD STIFFNESS WAS NOTED DURING AN ADDITIONAL FOLLOW-UP VISIT ON (B)(6) 2018. THE VOCAL FOLD STIFFNESS WAS REPORTED TO HAVE BEEN DIAGNOSED VIA A VIDEOSTROBOSCOPY AND THROUGH LISTENING TO THE PATIENT'S VOICE. DURING THE (B)(6) 2018 FOLLOW-UP APPOINTMENT, THE PHYSICIAN NOTED THAT THERE HAD BEEN "INTERVAL DECREASE IN VOCAL FOLD SIZE AND MILD IMPROVEMENT IN THE MOBILITY OF THE VOCAL FOLD." THE PATIENT'S VOCAL QUALITY WAS NOTED AS "SHARP AND DYSPHONIC" WITH "DIPLOPHONIA IN THE LOW RANGES." NO FURTHER TREATMENT WAS REPORTED BUT THE PHYSICIAN STATED THAT "BOTH SPEECH THERAPY AND MICROFLAP EXCISION OF THE REMAINING INJECTION MATERIAL" WERE OFFERED "WHICH THE PATIENT HAS DEFERRED." THE PATIENT'S CURRENT STATUS WAS REPORTED THAT HE "REMAINS WITH VOCAL FOLD STIFFNESS" AND THAT "HE DOES NOT WISH TO PURSUE FURTHER TREATMENT." A FOLLOW-UP APPOINTMENT WAS SCHEDULED FOR (B)(6) 2019 BUT THE PATIENT WAS REPORTED TO HAVE CANCELLED DUE TO "OTHER HEALTH CONCERNS." THE PHYSICIAN REPORTED THAT THE PATIENT PLANS TO FOLLOW-UP TO EVALUATE WHETHER THE VOCAL FOLD STIFFNESS IS PERMANENT BUT WISHES TO DEFER THE FOLLOW-UP AT THIS TIME FOR SEVERAL MONTHS. (B)(4).

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    21201 RENÚ GEL, 1.5CC SYSTEM, VOCAL CORD MEDIALIZATION, PRODUCT CODE: MIX MIX CYTOPHIL, INC. 08-015-00-V04 Y708-00047 00856509002935

    Patients

    Seq Age Sex Outcome Treatment
    1 57 YR Other